Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 8—August 2022
Research Letter

Household Secondary Attack Rates of SARS-CoV-2 Omicron Variant, South Korea, February 2022

Do Sang Lim1, Young June Choe1, Young Man Kim, Sang Eun Lee, Eun Jung Jang, Jia Kim, and Young-Joon ParkComments to Author 
Author affiliations: Korea Disease Control and Prevention Agency, Cheongju, South Korea (D.S. Lim, Y.M. Kim, S.E. Lee, E.J. Jang, J. Kim, Y.-J. Park); Korea University Anam Hospital, Seoul, South Korea (Y.J. Choe)

Main Article

Table

Household contacts, household infected cases, and secondary attack rate of SARS-CoV-2 Omicron variant, South Korea, February 1–10, 2022

Characteristic No. household contacts No. household infection cases Secondary attack rate, %
Total
 163,581
 59,982
 36.7
Sex
M* 80,145 27,595 34.4
F
 83,436
 32,387
 38.8
Age group, y
0–11* 18,456 10,173 55.1
12–17 13,266 5,839 44.0
18–29 26,243 8,497 32.4
30–39 15,920 7,006 44.0
40–49 31,477 12,497 39.7
50–59 33,920 9,302 27.4
60–74 18,037 5,056 28.0
>75
 6,262
 1,612
 25.7
Vaccine type†
Comirnaty/Pfizer-BioNTech* 87,296 29,808 34.1
Vaxzevria/AstraZeneca 1,638 610 37.2
Spikevax/Moderna 19,398 6,335 32.7
Jcovden/Janssen 261 128 49.0
Mix-and-match‡ 26,780 8,144 30.4
Unvaccinated 28,208 14,957 53.0

*p<0.001. †Pfizer-BioNTech, https://www.pfizer.com; AstraZeneca, https://www.astrazeneca.com; Moderna, https://www.modernatx.com; Janssen/Johnson & Johnsoh, https://www.janssen.com. ‡Heterologous (mix-and-match) vaccinations with mRNA vaccines were provided to AstraZeneca-primed and Janssen-primed persons.

Main Article

1These first authors contributed equally to this article.

Page created: June 30, 2022
Page updated: July 21, 2022
Page reviewed: July 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external